Pipeline

Our pipeline of four First-in-Class ADCs combines deep understanding of novel targets with optimized ADC technology for selected solid tumor indications. Our programs ADCE-T02 (targeting Tissue Factor) and ADCE-D01 (targeting uPARAP) are about to enter clinical stage of development, with additional programs currently at the IND-enabling and discovery stages.